Shaping the future of HER2-directed therapy in biliary tract cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41711894.
- Also identified by DOI 10.1158/1078-0432.CCR-25-4464.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This commentary on a retrospective study of patients with HER2 positive biliary tract cancer highlights the importance of reflex and validated HER2 testing criteria; the discordance of next generation sequencing and HER2 immunohistochemistry; the potential prognostic and predictive role of HER2; and the necessity to define HER2 therapy resistance mechanisms.